Real-world effectiveness of stroke prevention in patients with non-valvular atrial fibrillation treated with rivaroxaban vs. phenprocoumon in Germany - insights from the reload study

被引：0
|
作者：
Bonnemeier, H. [1 ]
Mundhenke, M. [2 ]
Von Mach, T. [2 ]
Huelsebeck, M. [2 ]
机构：
[1] Univ Med Ctr Schleswig Holstein, Dept Electrophysiol & Rhythmol, Kiel, Germany
[2] Bayer Vital GmbH, Leverkusen, Germany
来源：
EUROPEAN HEART JOURNAL | 2017年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P3581
引用
收藏
页码：765 / 765
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF RIVAROXABAN COMPARED WITH REAL-WORLD TREATMENT FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION IN CHINA
    Yang, L.
    Wu, J.
    [J]. VALUE IN HEALTH, 2018, 21 : S63 - S63
  • [2] RIVAROXABAN IN PREVENTION OF STROKE IN ELDERLY PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
    Yavelov, I. S.
    [J]. KARDIOLOGIYA, 2019, 59 (12) : 4 - 11
  • [3] COST-EFFECTIVENESS OF RIVAROXABAN FOR THE PREVENTION OF STROKE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION - A MULTINATIONAL STUDY
    Asukai, Y.
    Maniadakis, N.
    Carcedo, D.
    Lukac, M.
    Evers, T.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A285 - A285
  • [4] Dabigatran in 'real-world' clinical practice for stroke prevention in patients with non-valvular atrial fibrillation
    Potpara, Tatjana S.
    [J]. THROMBOSIS AND HAEMOSTASIS, 2015, 114 (06) : 1093 - 1098
  • [5] Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKETAF and XANTUS
    Camm, A. John
    Amarenco, Pierre
    Haas, Sylvia
    Hess, Susanne
    Kirchhof, Paulus
    Lambelet, Marc
    Bach, Miriam
    Turpie, Alexander G. G.
    [J]. EUROPACE, 2019, 21 (03): : 421 - 427
  • [6] Real - world evidence of stroke prevention in patients with non-valvular atrial fibrillation
    Coleman, C.
    Antz, M.
    [J]. EUROPEAN HEART JOURNAL, 2016, 37 : 502 - 502
  • [7] COST-EFFECTIVENESS OF RIVAROXABAN IN THE PREVENTION OF STROKE IN NON-VALVULAR ATRIAL FIBRILLATION PATIENTS IN ITALY
    Capri, S.
    Veneziano, M.
    Ricciardi, W. G.
    D'Ausilio, A.
    Pedone, M. P.
    Bianchi, C.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A525 - A526
  • [8] A REAL-WORLD ASSESSMENT OF RISK FOR SEVERE STROKE AND POST-STROKE MORTALITY IN NON-VALVULAR ATRIAL FIBRILLATION PATIENTS TREATED WITH RIVAROXABAN AND WARFARIN
    Alberts, Mark
    Chen, Yen-Wen
    Lin, Jennifer
    Ding, Zhijie
    Bisht, Deepti
    Kogan, Emily
    Twyman, Kathryn
    Milentijevic, Dejan
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 1862 - 1862
  • [9] Rivaroxaban for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation and Active Cancer
    Laube, Eva Simona
    Yu, Anthony
    Gupta, Dipti
    Miao, Yimei
    Samedy, Patrick
    Wills, Jonathan
    Harnicar, Stephen J.
    Soff, Gerald A.
    Mantha, Simon
    [J]. BLOOD, 2016, 128 (22)
  • [10] Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and heart failure
    Martinez, Brandon K.
    Bunz, Thomas J.
    Eriksson, Daniel
    Meinecke, Anna-Katharina
    Sood, Nitesh A.
    Coleman, Craig I.
    [J]. ESC HEART FAILURE, 2019, 6 (01): : 10 - 15
12345